Treating Unresectable Metastatic Colorectal Cancer

Panelists: Johanna Bendell, MD, Sarah Cannon; Axel Grothey, MD, Mayo Clinic; Claus-Henning Köhne, MD, PhD, Klinikum Oldenburg; John L. Marshall, MD, Georgetown-Lombardi;
Heinz-Josef Lenz, MD, USC Norris
Published Online: Monday, April 29, 2013
For High-Definition, Click
Treatment options for patients with unresectable metastatic colorectal cancer (CRC) have evolved from 5-FU to oxaliplatin, capecitabine, and targeted therapies. However, until recently, new drug development has been fairly stagnant, placing emphasis on the optimal use of existing treatments through the use of biological markers and molecular testing.

At this point, Heinz-Josef Lenz, MD, states, the only clinically validated predictive marker is KRAS, which is an oncogene in the MAP kinase pathway. The status of this gene plays a significant role in the efficacy of EGFR targeted treatments. However, Lenz notes, questions still linger over the optimal use of this marker, particularly the accuracy of tests and the exon of the mutation. Along these lines, in the future, the FDA will be more involved in the approval of molecular tests, Lenz believes.

Looking more closely at location, moderator John L. Marshall, MD, poises the question of selecting treatment for patients with KRAS G13D mutations. Johanna Bendell, MD, explains that recent findings contradict the initial pooled analysis of the CRYSTAL and OPUS trials, which showed that cetuximab was beneficial in patients with KRAS G13D mutations. As a result, she believes the role of the G13D is unclear and patients who test positive should be enrolled in clinical trials.

The role of BRAF mutations in CRC has evolved, as more data becomes available. Axel Grothey, MD, explains that approximately 8% of patients with metastatic CRC have a BRAF mutation. Unfortunately, Grothey notes, BRAF mutations denote a poorer prognosis and a standard therapy currently does not exist. The treatment of BRAF mutant metastatic CRC is evolving, Lenz states. Moreover, he notes, these tumors seem to respond to immunotherapies.

The need for effective treatment approaches in this space enhances the importance of molecular testing and enrollment in clinical trials. At this point, Bendell notes, research is just beginning to scratch the surface of what is possible in the treatment of CRC. The panel remains optimistic that a target will be found that shows dramatic responses, similar to those seen in lung cancer with ALK and EGFR and in breast cancer with HER2.
View More From This Discussion
Episode 1 Managing Adjuvant Treatment in Colorectal Cancer, Part I
Episode 2 Managing Adjuvant Treatment in Colorectal Cancer, Part II
Episode 3 Understanding the Role of Aspirin in Colorectal Cancer
Episode 4 Exploring the Neoadjuvant Treatment of Rectal Cancer
Episode 5 Treating Resectable Metastatic Colorectal Cancer
Episode 6 Treating Unresectable Metastatic Colorectal Cancer
Episode 7 Treatment Sequencing in Metastatic Colorectal Cancer
Episode 8 Determining Optimal Treatments in mCRC
Episode 9 Second-Line Therapies for Patients With mCRC
Episode 10 Case Study: Treating Metastatic Colorectal Cancer
Episode 11 Conclusion: Optimal Side Effect Management in CRC
Expert Panelists
Dr. John L. Marshall

John L. Marshall, MD

Professor, Chief, Division of Hematology/Oncology,
Georgetown University Hospital,
Associate Director, Clinical Research,
Lombardi Comprehensive Cancer Center,

Johanna Bendell, MD

Director, GI Oncology Research
Associate Director, Drug Development Unit
Sarah Cannon Research Institute
Nashville, TN

Axel Grothey, MD

Professor of Oncology and Consultant
Division of Medical Oncology
Department of Oncology, Mayo Clinic
Rochester, MN

Claus-Henning Köhne, MD, PhD

Professor of Medicine,
Department of Oncology/Hematology
Klinikum Oldenburg
Oldenburg, Germany

Heinz-Josef Lenz, MD

Co-Director, Colorectal Center and GI Oncology Program, USC Norris Comprehensive Cancer Center, Los Angeles, CA
Online CME Activities
Free CME from PER
PARP Inhibitors: Current and Future Options for Breast and Ovarian Cancer
Rapid Summaries and Commentaries: Update from Chicago - Advances in the Treatment of Lung Cancer
Medical Crossfire®: The JAK-STAT Pathway as a Mediator of Onco-Inflammation
2nd Annual Miami Lung Cancer Conference™ Medical Crossfire® Case Discussion
The content contained in this video is for general information purposes only. The viewer is encouraged to confirm the information presented with other sources. OncLiveTV Peer Exchange makes no representations or warranties of any kind about the completeness, accuracy, timeliness, reliability, or suitability of any of the information, including content or advertisements, contained in this video and expressly disclaims liability for any errors and omissions that may be presented in this video. OncLiveTV Peer Exchange reserves the right to alter or correct any error or omission in the information it provides in this video, without any obligations. OncLiveTV Peer Exchange further disclaims any and all liability for any direct, indirect, consequential, special, exemplary, or other damages arising from the use or misuse of any material or information presented in this video. The views expressed in this video are those of the panelists and do not necessarily reflect the opinion or policy of OncLiveTV Peer Exchange.
More Reading